Abstract:Objective: To explore metabolic disturbances in nonobese women with polycystic ovary syndrome (PCOS) compared with nonobese healthy controls. Design: Systematic review and meta-analysis. Setting: Not applicable. Patient(s): Nonobese women with PCOS and nonobese healthy controls. Intervention(s): None. Main outcome measure(s): Prevalence of metabolic disturbances including hyperinsulinemia, insulin resistance (IR), impaired fasting glucose (IFG), impaired glucose intolerance (IGT), prediabetes, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, and low high-density lipoprotein (low-HDL), as well as other metabolic outcomes such as type 2 diabetes mellitus (T2DM), hypertension, metabolic syndrome (Mets), myocardial infarction, stroke, cerebrovascular accident, arterial occlusive disease, and coronary heart disease. Result(s): Compared to nonobese controls, nonobese women with PCOS showed a higher prevalence of hyperinsulinemia (odds ratio [OR], 36.27; 95% confidence interval [CI] 1.76-747.12), IR (OR, 5.70; 95% CI 1.46-22.32), IGT (OR, 3.42; 95% CI 1.56-7.52), T2DM (OR, 1.47; 95% CI 1.11-1.93), hypertriglyceridemia (OR, 10.46; 95% CI 1.39-78.56), low-HDL (OR, 4.03; 95% CI 1.26-12.95), and Mets (OR, 2.57; 95% CI 1.30-5.07). No significant difference was observed for IFG, pre-DM, dyslipidemia, hypercholesterolemia, and hypertension. In subgroup analysis, Whites exhibited increased risks of IR, IGT, IFG, T2DM, hypertension, and Mets, whereas no significant metabolic change was found in Asians. No study reported specifically an incidence of myocardial infarction, stroke, cerebrovascular accident, arterial occlusive disease, and coronary heart disease in nonobese women with PCOS. Conclusion(s): Nonobese women with PCOS also suffer from metabolic disturbances and the risk of long-term metabolic complications. Further efforts should be made to elucidate underlying mechanisms and possible interventions in the early phase.

Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome

Polycystic Ovary Syndrome, Insulin Resistance, and Cardiovascular Disease

Polycystic ovary syndrome: associations with cardiovascular disease

Polycystic Ovary Syndrome: A Review of Diagnosis and Management, with Special Focus on Atherosclerotic Cardiovascular Disease Prevention

Update on the management of polycystic ovary syndrome

Cardiometabolic Risk, Peripheral Arterial Disease and Cardiovascular Events in Polycystic Ovary Syndrome: Time to Implement Systematic Screening and Update the Management

The Cardiometabolic Risk in Women with Polycystic Ovarian Syndrome (PCOS): From Pathophysiology to Diagnosis and Treatment

Subclinical cardiovascular disease and polycystic ovary syndrome

Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease

Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis

PCOS: metabolic impact and long-term management

2023 International Evidence-Based Polycystic Ovary Syndrome Guideline Update: Insights From a Systematic Review and Meta-Analysis on Elevated Clinical Cardiovascular Disease in Polycystic Ovary Syndrome

Molecular genetics of polycystic ovary syndrome: an update

Heart health in polycystic ovary syndrome: time to act on the data

Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update

The Importance of Diagnosing the Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS): Bridging Gaps in Understanding, Diagnosis, and Management

Polycystic ovary syndrome: treatment strategies and management

Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS)

Pathophysiology and Nutritional Approaches in Polycystic Ovary Syndrome (PCOS): A Comprehensive Review

A Molecular and Cellular Review of the Literature